GLP ‐1 receptor agonists and cardiovascular events in metabolically healthy or unhealthy obesity
Authors' conclusion
The use of GLP-1RAs was associated with lower rates of cardiovascular events than no use in patients with MUHO. Similar but non-statistically significant trends were seen in patients with MHO.
Study context
- Population
- Patients with obesity, metabolically healthy (metabolically healthy obesity (MHO)) or unhealthy (metabolically unhealthy obesity (MUHO)), TriNetX network416,713 GLP-1RA users
- Participants
- 2,983,151 patients
- Exposure
- GLP-1 RA use vs non-use in MHO and MUHO
- Outcome
- Mortality and adverse cardiovascular events
Methodological detailspropensity score matching (1:1), TriNetX network
- Propensity score matching (1:1)
- TriNetX network
Main finding
As reported in the abstract
Outcomes in MUHO (after propensity score matching) · follow-up
GLP-1RA vs Non-useHazard ratio (95% CI)
Mortality, MUHO
0.580(0.566–0.595)
Ischemic stroke, MUHO
0.921(0.890–0.953)
AF, MUHO
0.913(0.888–0.938)
Hospitalization for HF, MUHO
0.925(0.900–0.949)
Observational data: associations, not effects.
Further findings
- MHO had a markedly lower risk of clinical events than MUHO
Original publication
GLP ‐1 receptor agonists and cardiovascular events in metabolically healthy or unhealthy obesity. Diabetes Obes Metab. Published 10 February 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →